Effect of atorvastatin and clopidogrel co-administration after coronary stenting in Korean patients with stable angina

Korean Circulation Journal

Volumn 41, Issue 1, 2011, Pages 28-33

  Kim, Goeng Bae ^a   Kim, Jeong Kyung ^a   Park, Sul ^a   Jeong, Jae Jin ^a   Yoon, Hyung Sik ^a   Ko, Sang Hun ^a   Ko, Jae Ee ^a   Park, Soo Jin ^a   Nam, Seon Woo ^a   Lee, Jae Hwan ^b   Hyon, Min Soo ^c  

^a Sun General Hospital   (South Korea)

^b Chungnam National University College of Medicine   (South Korea)

^c Soonchunhyang University   (South Korea)

Author keywords

Atorvastatin; Cardiovascular diseases; Clopidogrel; Cytochrome P450 3A4 protein, human; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; NITRATE;

ADULT; ARTICLE; CORONARY STENT; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; KOREA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; STABLE ANGINA PECTORIS; THROMBOCYTE AGGREGATION;

EID: 79952344114     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2011.41.1.28     Document Type: Article

References (32)

1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
2. Chae SC. Antiplatelet agents in high-risk patients with coronary artery disease. Korean Circ J 2004;34:23-7.
3. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102:624-9. (Pubitemid 30640661)
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502. (Pubitemid 32758501)
5. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. JAm Coll Cardiol 2002;39:9-14. (Pubitemid 34059855)
6. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9. (Pubitemid 26120185)
7. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis ofmulticenter coronary stent clinical trials. Circulation 2001;103:1967-71. (Pubitemid 32322224)
8. Shömig A, Mehilli J, Holle H, et al. Statin treatment following coronary stenting and one-year survival. J Am Coll Cardiol 2002;40: 854-61. (Pubitemid 34994977)
9. Baek JH, Choe KH, Jun JE, et al. Multicenter clinical trial of atorvastatin inpatients with hypercholesterolemia. Korean Circ J 2001;31: 434-41.
10. Yun KH, Park HY, Choi JH, et al. Comparison of efficacy and safety after administering high potency statin to high risk patients: rosuvastatin 10 mg versus Atorvastatin 20 mg. Korean Circ J 2007;37:154-60.
11. Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992;44:527-32.
12. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994;72:313-7. (Pubitemid 24251300)
13. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84:891-6.
14. Clarke TA, Wakell LA. The metabolism of clopidogrel is catalyzed by human cytochrome p450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-9. (Pubitemid 36735258)
15. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-7. (Pubitemid 36070929)
16. Neubauer H, Günesdogan B, Hanefeld C, Spiecker M, Mügge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function: a flow cytometry study. Eur Heart J 2003;24:1744-9. (Pubitemid 37236863)
17. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrelatorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003;108:921-4. (Pubitemid 37048218)
18. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92:285-8. (Pubitemid 36897711)
19. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335-8. (Pubitemid 38387816)
20. Serebruany VL, Midei MG, Malinin Al, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004;164:2051-7. (Pubitemid 39390564)
21. Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA. Lack of clopidogrel-CYP3A4 statin interaction inpatients with acute coronary syndrome. Heart 2005;91:23-6. (Pubitemid 39664985)
22. Geisler T, Zürn C, Paterok M, et al. Statins do not adversely affect postinterventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J 2008;29:1635-43. (Pubitemid 351957543)
23. Hong SJ, Park JY, Kim KA, et al. Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Koreanpatients with acute coronary syndrome. Circ J 2009;73:1111-8.
24. World Medical Association. WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html (accessed 2 December 2008).
25. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13. (Pubitemid 30044262)
26. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible Statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-91.
27. Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphism of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008;72:1165-9. (Pubitemid 351957086)
28. Lee KH, Lee SW, Lee JW, et al. The significance of clopidogrel lowresponsiveness on stent thrombosis and cardiac death assessed by the verifynow P2Y21 assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation. Korean Circ J 2009; 39:512-8.
29. Mach F, Senouf D, Fontana P, et al. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest 2005;35:476-81. (Pubitemid 41153201)
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
31. Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. New York: Marcel Dekker;1999.
32. Chow SC, Shao J, Wang H. Sample Size Calculations in Clinical Research. New York: Marcel Dekker;2003.